Call us now on: +44 (0) 1223 743170

Discovery STAR Award

Supporting Translational Academic Research

Domainex is committed to the support of exciting and cutting edge translational research. From its foundations out of The Institute of Cancer Research (ICR), Birkbeck College and UCL, to its on-going work with St George’s University, The University of Manchester and ICR; Domainex has exemplified how academic-private sector drug discovery collaborations can succeed and be beneficial to all parties.

Domainex launched its Discovery STAR award in 2013, to support the early stages of drug discovery for a chosen number of applicants to the scheme. At Domainex’s discretion, selected applicants will then be provided with drug discovery advice and/or virtual hit screening 1 free of charge in order to bridge the gap between academic grants and drug discovery funding schemes such as the Wellcome Trust SDDI, Technology Strategy Board, Biomedical Catalyst Fund or MRC DPFS 2.

  • Domainex will operate the Discovery STAR award once per year. The next round deadline is shown below. If you have questions, please contact Joanne McCudden at joanne.mccudden@domainex.co.uk.
  • Domainex will treat any information provided as confidential, but is willing to enter into a non-disclosure agreement with an applicant if this is preferred.

In order to apply, please provide us with the following details (we recommend you save your text in case of problems after submitting!). Applications are welcome using this electronic form or directly to joanne.mccudden@domainex.co.uk

STAR award application deadline: 30th September 2014

Name
Academic Institute
Position
Email
Title of Project

Project summary

Please include information such as:

  • novelty of drug target or indication
  • are biochemical assays established to enable testing of the screening set to be proposed by Domainex following the award? Are these already established within the applicants laboratories? Please describe in detail the format and throughput of this assay and the source of reagents
  • is structural information of the target, its homologues or known ligand information available to enable a virtual screen to be completed? Please describe.
  • does the project address a significant unmet medical need?
  • Virtual screening will result in a proposed screening set tailored to your target and clinical indication. Do you have funding available to enable the purchase of min. 200-500 compounds from 3rd parties at an average of £30/cpd, or will you seek additional funds to support this? (see footnote 1)
  • what is your plan following successful hit identification, i.e. a wish to attract further funding to support a larger drug discovery project?
N.B. If you receive an error message after clicking submit, your application will not have been sent. In case of technical problems, please email your application to: Joanne.McCudden@domainex.co.uk

1 No compound purchase from 3rd party suppliers is included and the cost of these must be found by the award recipient.

2 No cash alternatives to the award available.